Workflow
药物授权合作
icon
搜索文档
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
WSJ· 2025-10-15 13:17
Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart. ...